Kallikrein-10 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Kallikrein-10 (UniProt O43240), expressed in HEK293 cells. Suitable for serine protease activity assays, inhibitor profiling, substrate identification, and antibody validation as a positive control standard.
Expression system
HEK293
Cat. #
REC-Kallikrein10

In stock

SKU
REC-Kallikrein10
$498.00

Target Overview

Kallikrein-10 (KLK10; UniProt O43240) is a secreted serine protease of the tissue kallikrein family, encoded by the KLK10 gene on chromosome 19q13.4. The full-length precursor spans 276 amino acids and is processed to an active form following signal peptide and propeptide removal, consistent with the zymogen maturation pattern shared across kallikrein-related peptidases (KLKs). Like other secreted KLKs, mature KLK10 harbours a canonical chymotrypsin-fold catalytic triad and exhibits trypsin- or chymotrypsin-like substrate preference depending on conditions. This recombinant is produced in HEK293 cells, a mammalian expression system that supports native-like N-linked glycosylation and disulfide bond formation — both relevant to secreted serine proteases whose folding and activity can be sensitive to expression host. HEK293-derived KLK10 is therefore well-suited for enzymatic characterisation under conditions that approximate the extracellular milieu. Researchers use this recombinant in several contexts: (1) fluorogenic or chromogenic peptide-substrate cleavage assays to establish enzyme activity and kinetic parameters (Km, kcat); (2) inhibitor IC50 determinations, including profiling of serine protease inhibitor scaffolds; (3) substrate identification experiments, where candidate substrates such as desmoglein 3 can be tested directly; and (4) as a well-defined positive-control antigen for antibody validation by Western blot, ELISA, or dot blot. Researchers validating detection reagents can pair this recombinant with the matched Triple Point Biologics antibody (SKU: RP-Kallikrein10), which has been validated for Western blot applications. The defined sequence and expression system of this recombinant allow clean interpretation of band identity and signal specificity.

Background

KLK10 (Kallikrein-10) is a member of the 15-gene human tissue kallikrein locus, a cluster of structurally related serine proteases implicated in diverse physiological processes including skin desquamation, neural function, and extracellular matrix remodelling. The protein was originally described under the name NES1 (Normal Epithelial Cell-Specific 1) following its identification as a transcript downregulated in transformed breast epithelial cells, a finding that initially framed KLK10 as a candidate tumour suppressor. Subsequent research has substantially complicated that picture. KLK10 expression patterns and functional consequences appear highly context-dependent, varying by tumour type, disease stage, and epigenetic state. In breast cancer, promoter methylation of KLK10 has been studied as a candidate biomarker; Yang JC et al. (2025) examined the association between KLK10 gene methylation in female breast tumour tissue and the risk of invasive breast cancer, illustrating how epigenetic silencing of this locus is investigated in basic cancer biology. In contrast, Eisenhauer J et al. (2026) reported that KLK10 and its substrate desmoglein 3 are upregulated in early-stage pancreatic cancerous lesions, positioning KLK10 enzymatic activity as a potential marker of early neoplastic change and making substrate-cleavage studies with this recombinant directly relevant to that research programme. In rectal cancer, Chou CL et al. (2026) characterised KLK10 upregulation as a driver of tumour aggressiveness and radioresistance with negative prognostic impact — a finding that exemplifies how researchers use recombinant KLK10 to interrogate protease-dependent signalling pathways. Separately, Xuan Z et al. (2025) investigated crosstalk between KLK10-expressing epithelial cells and fibroblasts in the context of liver metastasis of breast cancer and pancreatic ductal adenocarcinoma, highlighting interstitial protease activity as a subject of ongoing mechanistic study. The regulatory complexity of KLK10 expression is further underscored by Yang J et al. (2026), who demonstrated that the lncRNA TMPO-AS1 modulates cisplatin resistance in cervical cancer through a miR-140-5p/DNMT1 axis that controls KLK10 DNA methylation — an example of how KLK10 expression serves as a functional readout in epigenetic and non-coding RNA research. For in-vitro studies across all these contexts, recombinant KLK10 provides a defined, active enzyme for substrate cleavage experiments, inhibitor profiling, and protein–protein interaction studies without the confounders inherent to cell lysate-based approaches.

Applications

  • Fluorogenic peptide-substrate cleavage assay to determine KLK10 kinetic parameters (Km, kcat/Km)
  • Serine protease inhibitor IC50 profiling using chromogenic or fluorogenic substrate competition formats
  • Desmoglein 3 or extracellular matrix protein substrate cleavage confirmation by SDS-PAGE or mass spectrometry
  • Antibody validation positive control for Western blot and ELISA (pair with RP-Kallikrein10)
  • Binding affinity measurement (SPR or BLI) for serpin-class or synthetic inhibitor candidates
  • Pull-down or co-immunoprecipitation bait protein to identify KLK10 interaction partners in cell lysates
  • ELISA standard curve antigen for quantification of endogenous KLK10 in conditioned media or tissue extracts

References

  1. Chou CL et al. KLK10 Upregulation Drives Aggressiveness and Radioresistance and Has a Negative Prognostic Impact on Rectal Cancer. Lab Invest. 2026. doi:10.1016/j.labinv.2026.106128 PMID: 42019595
  2. Eisenhauer J et al. Kallikrein related peptidases 7 and 10 and their substrate desmoglein 3 are upregulated in early stage pancreatic cancerous lesions. Sci Rep. 2026. doi:10.1038/s41598-026-48628-7 PMID: 41974993
  3. Yang J et al. LncRNA TMPO-AS1 aggravates the cisplatin resistance in cervical cancer via miR-140-5p/DNMT1 axis-mediated DNA methylation of KLK10. Med Oncol. 2026. doi:10.1007/s12032-025-03233-y PMID: 41642421
  4. Yang JC et al. [Association between KLK10 gene methylation in female breast tumor tissue and the risk of invasive breast cancer]. Zhonghua Yi Xue Za Zhi. 2025. doi:10.3760/cma.j.cn112137-20241202-02707 PMID: 40399130
  5. Xuan Z et al. SCGB3A1-Epi and KLK10-Epi Crosstalk With Fibroblasts Promotes Liver Metastasis of Breast Cancer and Pancreatic Ductal Adenocarcinoma. Cancer Med. 2025. doi:10.1002/cam4.70904 PMID: 40357856

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma; tissue

Frequently Asked Questions

What molecular weight should I expect for recombinant Kallikrein-10 on SDS-PAGE or Western blot?

The mature, processed form of KLK10 runs at approximately 26–30 kDa under reducing SDS-PAGE conditions. The apparent MW on gel typically exceeds the theoretical ~26 kDa of the core polypeptide due to N-linked glycosylation added during HEK293 expression. Under non-reducing conditions, disulfide-dependent compaction may shift the band slightly. If you are running a Western blot positive control alongside our matched antibody RP-Kallikrein10, load 50–100 ng per lane and expect a diffuse or doublet band in the 26–32 kDa range consistent with glycoform heterogeneity.

What processing form is this recombinant Kallikrein-10 — zymogen or active enzyme?

REC-Kallikrein10 is supplied as the active, mature enzyme following signal peptide and propeptide removal, consistent with the zymogen maturation pattern of kallikrein-related peptidases. It is not a pro-form. The catalytic triad (His-Asp-Ser) is intact and the enzyme is active as supplied. No additional activation step is required before use in activity assays. If your experiment specifically requires the zymogen precursor for maturation studies, contact us — but for substrate cleavage, inhibitor profiling, or antibody validation work, the active form is appropriate.

What substrates does recombinant Kallikrein-10 cleave and what is its protease class?

KLK10 is a secreted serine protease with a chymotrypsin-fold catalytic mechanism. Depending on assay conditions, it can exhibit trypsin-like (cleaving after Arg/Lys) or chymotrypsin-like (cleaving after Phe/Tyr/Leu) substrate preferences. For fluorogenic activity assays, Boc-Val-Pro-Arg-AMC (trypsin-like) and Suc-Ala-Ala-Pro-Phe-AMC (chymotrypsin-like) are commonly used substrates. Run both substrate types alongside a blank (buffer only) to determine which preference predominates under your specific buffer and pH conditions before committing to downstream inhibitor or substrate profiling experiments.

What buffer and pH conditions work best for a Kallikrein-10 activity assay?

REC-Kallikrein10 is stored in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. For activity assays, dilute into a working buffer of 50–100 mM Tris-HCl or PBS at pH 7.4–8.0; serine protease activity is generally attenuated below pH 6.5. Include 0.01–0.05% BSA or Tween-20 to minimize surface adsorption at low enzyme concentrations. Avoid EDTA-containing buffers, as divalent cation chelation can indirectly affect assay components. A starting enzyme concentration of 1–5 nM in the assay well is reasonable for initial Km/Vmax determination with AMC-tagged peptide substrates.

What starting concentration of recombinant Kallikrein-10 should I use for an inhibitor IC50 assay?

For inhibitor IC50 determination, use the lowest enzyme concentration that gives a robust, linear fluorescence signal above background — typically 1–5 nM KLK10 in a 100 µL assay volume with substrate at or near the Km (start at 50–200 µM for AMC-tagged substrates). Running enzyme significantly above Km will compress the apparent IC50 of competitive inhibitors, so titrate enzyme and substrate concentrations in a preliminary experiment. Include serine protease inhibitor PMSF (1 mM final) as a positive inhibition control to confirm assay sensitivity before running compound plates.

Can I use recombinant Kallikrein-10 as a Western blot positive control for the RP-Kallikrein10 antibody?

Yes — REC-Kallikrein10 and RP-Kallikrein10 are produced and validated together in the same lab specifically for this purpose. Load 50–100 ng of recombinant protein per lane on a 12–15% SDS-PAGE gel (reducing conditions) and transfer to PVDF or nitrocellulose. The rabbit polyclonal RP-Kallikrein10 is validated for Western blot and should be used at 1:500–1:2,000 depending on your secondary antibody system. The expected band at 26–32 kDa provides a clean reference when troubleshooting low or absent signal in cell lysate or tissue samples. See /anti-kallikrein-10-rabbit-polyclonal-antibody for full validation data.

How much recombinant Kallikrein-10 should I load as a positive control alongside RP-Kallikrein10 for IHC antibody validation?

For Western blot antibody validation alongside RP-Kallikrein10, 50–100 ng per lane is a reliable starting point. If you are establishing a dilution curve to demonstrate antibody linearity — useful for IHC validation papers — load 25, 50, and 100 ng lanes in parallel with a KLK10-positive cell lysate (e.g., LNCaP or MCF-7). This bracketing approach demonstrates dose-dependent signal and confirms the band identity before you commit to IHC optimization. Note that RP-Kallikrein10 is validated for WB (immunohistochemistry (IHC) and immunofluorescence (IF) validation in progress); see the antibody page at /anti-kallikrein-10-rabbit-polyclonal-antibody for species cross-reactivity data.

How should I store and handle recombinant Kallikrein-10 to maintain enzymatic activity over time?

Store REC-Kallikrein10 at -20°C in single-use aliquots as supplied. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is formulated to stabilize active serine proteases during frozen storage. Avoid repeated freeze-thaw cycles — each cycle can reduce specific activity due to partial denaturation. On the day of use, thaw on ice and dilute immediately into assay buffer with a carrier protein such as 0.1% BSA if working below 10 nM. Do not vortex; mix gently by pipette. Properly stored aliquots are stable for at least 12 months from date of receipt.

Validation imagery coming soon

Western blot validation figures for REC-Kallikrein10 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →